DE60041399D1 - Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen - Google Patents

Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen

Info

Publication number
DE60041399D1
DE60041399D1 DE60041399T DE60041399T DE60041399D1 DE 60041399 D1 DE60041399 D1 DE 60041399D1 DE 60041399 T DE60041399 T DE 60041399T DE 60041399 T DE60041399 T DE 60041399T DE 60041399 D1 DE60041399 D1 DE 60041399D1
Authority
DE
Germany
Prior art keywords
treatment
ischemic
inhibitors
protein
related diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60041399T
Other languages
English (en)
Inventor
Thomas Varming
Frank Waetjen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Painceptor Pharma Corp
Original Assignee
Painceptor Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Painceptor Pharma Corp filed Critical Painceptor Pharma Corp
Application granted granted Critical
Publication of DE60041399D1 publication Critical patent/DE60041399D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60041399T 1999-05-19 2000-05-12 Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen Expired - Fee Related DE60041399D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900695 1999-05-19
PCT/DK2000/000257 WO2000071102A2 (en) 1999-05-19 2000-05-12 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders

Publications (1)

Publication Number Publication Date
DE60041399D1 true DE60041399D1 (de) 2009-03-05

Family

ID=8096483

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041399T Expired - Fee Related DE60041399D1 (de) 1999-05-19 2000-05-12 Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen

Country Status (8)

Country Link
US (4) US6727260B2 (de)
EP (1) EP1183025B1 (de)
AT (1) ATE420636T1 (de)
AU (1) AU4910500A (de)
CA (1) CA2369746A1 (de)
DE (1) DE60041399D1 (de)
DK (1) DK1183025T3 (de)
WO (1) WO2000071102A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420636T1 (de) * 1999-05-19 2009-01-15 Painceptor Pharma Corp Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
CN1298704C (zh) * 2000-01-24 2007-02-07 神经研究公司 具有神经营养活性的靛红衍生物
EP1361874A1 (de) * 2001-02-15 2003-11-19 Neurosearch A/S Behandlung von durch übermässigen oder unzureichendem zelltod gekennzeichneten erkrankungen
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
CA2630617C (en) * 2005-11-23 2014-03-25 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20080004306A1 (en) * 2006-04-10 2008-01-03 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US7598039B2 (en) * 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
US20090246134A1 (en) * 2007-05-30 2009-10-01 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2009042797A1 (en) * 2007-09-27 2009-04-02 Honeywell International Inc. Method and system for repairing potholes in roads
WO2013134518A1 (en) * 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3333994A1 (de) * 1983-09-21 1985-04-04 Troponwerke GmbH & Co KG, 5000 Köln Neue pyridoindolderivate, verfahren zu ihrer herstellung und ihre verwendung
IE69677B1 (en) * 1989-12-11 1996-10-02 Neurosearch As Isatine derivatives their preparation and use
EP0510068B1 (de) * 1990-01-11 1999-04-14 PHARMACIA & UPJOHN COMPANY 6,7,8,9-tetrahydro-3h-benz(e)indolheterocyclen mit wirkung auf das zentrale nervensystem
AU655643B2 (en) * 1991-07-09 1995-01-05 Neurosearch A/S Novel isatineoxime derivatives, their preparation and use
CA2076948C (en) * 1991-08-28 2002-04-16 Frank Watjen Isatineoxime derivatives, their preparation and use
US5242918A (en) * 1991-08-28 1993-09-07 Neurosearch A/S Isatinoxime derivatives, their preparation and use
US5436250A (en) * 1991-08-28 1995-07-25 Neurosearch A/S Isatineoxime derivatives, their preparation and use
ATE161259T1 (de) * 1993-05-13 1998-01-15 Neurosearch As Ampa antagonisten und behandlungsmethode
US5843945A (en) * 1993-05-13 1998-12-01 Neurosearch A/S AMPA antagonists and a method of treatment
DK81593D0 (da) * 1993-07-07 1993-07-07 Neurosearch As Nye isatinoximderivater, deres fremstilling og anvendelse
US5917053A (en) * 1994-09-14 1999-06-29 Neurosearch A/S Indole-2,3-dione-3-oxime derivatives, their preparation and use
DE69514533T2 (de) * 1994-09-14 2000-07-06 Neurosearch A/S, Ballerup Kondensierte indole und chinoxalinderivate, ihre herstellung und verwendung als glutamatantagonisten
UA54403C2 (uk) * 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
FR2759373B1 (fr) * 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
GB9718365D0 (en) * 1997-08-29 1997-11-05 Univ London Ion channel proteins
EP1025226B1 (de) 1997-10-29 2006-12-06 McGill University Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen
DE69922936T2 (de) * 1998-03-31 2005-12-08 Neurosearch A/S Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
AU3348500A (en) 1999-01-22 2000-08-07 Millennium Pharmaceuticals, Inc. A novel acid sensing ion channel and uses thereof
US6789252B1 (en) * 1999-04-15 2004-09-07 Miles D. Burke Building business objects and business software applications using dynamic object definitions of ingrediential objects
ATE420636T1 (de) * 1999-05-19 2009-01-15 Painceptor Pharma Corp Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
US6941323B1 (en) * 1999-08-09 2005-09-06 Almen Laboratories, Inc. System and method for image comparison and retrieval by enhancing, defining, and parameterizing objects in images
US6591377B1 (en) * 1999-11-24 2003-07-08 Unisys Corporation Method for comparing system states at different points in time
TWI271406B (en) * 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
CN1298704C (zh) 2000-01-24 2007-02-07 神经研究公司 具有神经营养活性的靛红衍生物
US7084152B2 (en) * 2000-07-11 2006-08-01 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
AU2001271611A1 (en) * 2000-09-01 2002-03-22 Glaxo Group Limited Oxindole derivatives
EP1361878A1 (de) 2001-02-15 2003-11-19 Neurosearch A/S Behandlung von morbus parkinson mit der kombinierten wirkung einer verbindung mit neurotroper aktivität und einer verbindung zur verbesserung der dopamin-aktivität
MXPA03009185A (es) * 2001-04-09 2004-02-17 Neurosearch As Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
JP2006503011A (ja) 2002-08-22 2006-01-26 ニューロサーチ、アクティーゼルスカブ インドール−２，３−ジオン−３−オキシム誘導体の対掌体の製造方法
AU2003301439A1 (en) * 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
CA2630617C (en) * 2005-11-23 2014-03-25 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels

Also Published As

Publication number Publication date
EP1183025B1 (de) 2009-01-14
ATE420636T1 (de) 2009-01-15
US20040142936A1 (en) 2004-07-22
CA2369746A1 (en) 2000-11-30
WO2000071102A3 (en) 2001-03-15
US20080269230A1 (en) 2008-10-30
WO2000071102A2 (en) 2000-11-30
AU4910500A (en) 2000-12-12
DK1183025T3 (da) 2009-05-04
US6727260B2 (en) 2004-04-27
EP1183025A2 (de) 2002-03-06
US20060079529A1 (en) 2006-04-13
US20020058663A1 (en) 2002-05-16
US7288653B2 (en) 2007-10-30

Similar Documents

Publication Publication Date Title
MY133667A (en) Quinazoline ditosylate salt compounds
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
MY140767A (en) Compounds, methods and compositions
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
DE60231439D1 (de) Mitotische kinesinhemmer
DE60234278D1 (de) Mitotische kinesin-hemmer
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
DE60037013D1 (de) Neurotropische substituierte pyrimidine
ECSP034568A (es) Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona
PT1044197E (pt) Carboxamidas de piridilalcano, -alceno e -alcino substituidas por piperidinilo como agentes citostaticos e imunossupressores
ATE433966T1 (de) Methylendipiperidinderivate
TW200503710A (en) Novel compounds
GB0111186D0 (en) Novel compounds
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
TW200514781A (en) Novel compounds
DE60041399D1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
UY26426A1 (es) Nuevos compuestos
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DE60023139D1 (de) Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
NO20053562L (no) Nye aminobenzofenonforbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee